Australia's most trusted
source of pharma news
Monday, 02 June 2025
Posted 28 May 2025 AM
A major player in the biosimilar space is splitting from its parent company, with plans to begin its own research into novel medicines.
Samsung Biologics, the parent company of biosimilar producer Samsung Bioepis, has announced plans to split the company in October this year. Samsung Biologics will remain with the CDMO arm of the business, while Samsung Bioepis will be moved as a subsidiary under the tentatively-named new company, Samsung Episholdings.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.